Britain and America have announced a key trade agreement that will guarantee no import taxes on British medicine shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial exports will remain at nothing for a period of 36 months.
This deal is in response to previous warnings to hike import taxes on branded drug imports, with potential rates discussed as high as double the cost.
"This deal between the Britain reinforces the international landscape for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," an announcement said.
Trade Importance
Medicines represent one of the Britain's largest exports to the America, which is easily the largest destination for leading UK drugmakers.
Trade data reveal that in the 12 months prior to the third quarter, the UK exported medicines totaling £11.1bn to the US. This value made up 17.4% of British export trade in that period.
"This agreement secures employment, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for life sciences," a minister commented.
Specific UK Commitments
The agreement involves several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Last year, repayments were more than twenty percent.
Broader Context
The deal comes amid a protracted tension between the drug companies and the ministers over spending levels and approval rates.
This friction were intensified by assertions that American consumers were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been announced toward US facilities.
A senior figure stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
